Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 8, 2013, Pages 5754-5760

  Gillies, Mark C ^a   Walton, Richard ^a   Simpson, Judy M ^b   Arnold, Jennifer J ^c   Guymer, Robyn H ^d   McAllister, Ian L ^e   Hunyor, Alex P ^a,f   Essex, Rohan W ^g   Morlet, Nigel ^e   Barthelmes, Daniel ^a,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Marsden Eye Specialists   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Retina Associates   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anti VEGF; Neovascular age related macular degeneration; Observational study

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; CLINICAL TRIAL; ELECTRONIC MEDICAL RECORD; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

ANTI-VEGF; NEOVASCULAR AGE-RELATED MACULAR DEGENERATION; OBSERVATIONAL STUDY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; CLINICAL AUDIT; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84883213217     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11993     Document Type: Article

References (25)

1. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393-11398.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
4. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119: 1388-1398.
5. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
6. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157-1158.
7. Traynor K. Aflibercept approved for macular degeneration. Am J Health Syst Pharm. 2012;69:6.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58. e1.
9. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134-2140.
10. Gillies MC, Walton R, Liong J, et al. Efficient capture of high quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project [published online ahead of print June 3, 2013]. Retina. doi:10.1097/IAE.0b013e318296b271.
11. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
12. Cleveland W. LOWESS: a program for smoothing scatterplots by robust locally weighted regression. Am Stat. 1981;35:54.
13. Kleinbaum DG, Klein M. Chapter 2: Kaplan-Meier survival curves and the log-rank test. In: Survival Analysis: A Self-Learning Text. New York, NY: Springer; 2005:45-82.
14. R: A Language and Environment for Statistical Computing: Foundation for Statistical Computing.
15. DiCiccio TJ, Efron B. Bootstrap confidence intervals (with Discussion). Statistical Science. 1996;11:189-228.
16. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol. 2011;2011:405724.
17. Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany [published online ahead of print November 22, 2012]. Acta Ophthalmol. doi:10.1111/j.1755-3768.2012. 02493.x.
18. Heimes B, Lommatzsch A, Zeimer M, et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefe's Arch Clin Exp Ophthalmol. 2011;249:639-644.
19. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2012;33:474-481.
20. Menghini M, Kloeckener-Gruissem B, Fleischhauer J, et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular agerelated macular degeneration. PLoS One. 2012;7:e42014.
21. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-252.
22. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857.
23. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122-129.
24. Brown DM, Tuomi L, Shapiro H. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013;33:23-34.
25. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. Arch Ophthalmol. 1982;100:289-292.